MedPage Today - "Drug Combo Scores Early Against HCV and HIV"

 – March 5, 2013  –– 

A protease inhibitor being investigated in patients co-infected with the hepatitis C virus (HCV) and HIV yielded good early success when combined with pegylated interferon and ribavirin. In the so-called STARTVerso 4 trial, 80 percent of patients had undetectable HCV after eight weeks of therapy with faldaprevir, according to Douglas Dieterich, MD, of The Icahn School of Medicine at Mount Sinai. Learn more